

## Prostate Cancer Roundtable

www.prostatecancerroundtable.net  
P.O. Box 77476, Washington, DC 20013  
www.prostatecancerroundtable.net/contact-us

### Prostate Cancer Policy Agenda – 2015 - 2016

America's nationally-based prostate cancer organizations have developed a shared, national policy agenda — in the interests of the hundreds of thousands of American men who are at risk each year for a diagnosis of prostate cancer and more than 2 million men living today who have been diagnosed with this highly prevalent form of cancer.

The 2015-15 Prostate Cancer Policy Agenda:

- We continue to seek an appropriations increase to support the successful research activities of the **Prostate Cancer Research Program** within the Department of Defense's **Congressionally Directed Medical Research Program** – from its current \$80 million to \$120 million per year.
- We join with the broader cancer community to support increased federal appropriations for cancer research for the **National Institutes of Health**, the **National Cancer Institute**, and the **Centers for Disease Control and Prevention**.
- We support an increase to \$400 million per year from the current funding level of \$288 million for basic and translational prostate cancer research at the **National Cancer Institute**.
- We seek passage of a bill to create an Office on Men's Health within the Department of Health and Human Services (HHS) that can mirror the successes of the **Office on Women's Health** established in 1991.
- We support legislative, research, and educational efforts needed to effectively combat – and ideally to eliminate — the epidemic of prostate cancer among **African American men**.
- We propose the establishment of a Prostate Cancer Scientific Advisory Board for the **Office of the Chief Scientist** at the **U.S. Food & Drug Administration** (FDA), with the goal of accelerating the real-time sharing of research data and the movement of new medicines into clinical practice in the best interests of patients.
- We support revisions to the decision-making processes of the **U.S. Preventive Services Task Force (USPSTF)** to ensure appropriate input from representatives of patient advocacy groups, specialty medical groups, and other federal agencies that have expertise in each area of preventive services under review.
- We encourage the inclusion of **quality-of-life-related endpoints**, based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival — such that quality-of-life-related data (positive or negative) and survival data can be included in labeling for products indicated for treatment of prostate cancer when appropriate.

*Effective January 1, 2015*